TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
9.21
+0.60 (6.97%)
Aug 12, 2025, 12:38 PM CST
6.97%
Market Cap6.18B
Revenue (ttm)151.47M
Net Income (ttm)-55.07M
Shares Out717.84M
EPS (ttm)-0.08
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,652,333
Average Volume858,654
Open8.61
Previous Close8.61
Day's Range8.61 - 9.47
52-Week Range7.44 - 15.15
Beta0.16
RSI55.91
Earnings DateAug 22, 2025

About Paramount Global

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.